- Home
- RAYA vs CVKD Comparison
RAYA vs CVKD Comparison
Compare RAYA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAYA
- CVKD
- Stock Information
- Founded
- RAYA 2019
- CVKD 2022
- Country
- RAYA China
- CVKD United States
- Employees
- RAYA N/A
- CVKD N/A
- Industry
- RAYA Metal Fabrications
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- RAYA Consumer Discretionary
- CVKD Health Care
- Exchange
- RAYA Nasdaq
- CVKD Nasdaq
- Market Cap
- RAYA 34.2M
- CVKD 33.7M
- IPO Year
- RAYA 2022
- CVKD 2023
- Fundamental
- Price
- RAYA $1.32
- CVKD $15.50
- Analyst Decision
- RAYA
- CVKD Strong Buy
- Analyst Count
- RAYA 0
- CVKD 1
- Target Price
- RAYA N/A
- CVKD $32.00
- AVG Volume (30 Days)
- RAYA 22.2K
- CVKD 21.0K
- Earning Date
- RAYA 01-01-0001
- CVKD 05-08-2025
- Dividend Yield
- RAYA N/A
- CVKD N/A
- EPS Growth
- RAYA N/A
- CVKD N/A
- EPS
- RAYA N/A
- CVKD N/A
- Revenue
- RAYA $30,300,360.00
- CVKD N/A
- Revenue This Year
- RAYA $20.95
- CVKD N/A
- Revenue Next Year
- RAYA N/A
- CVKD N/A
- P/E Ratio
- RAYA N/A
- CVKD N/A
- Revenue Growth
- RAYA 49.10
- CVKD N/A
- 52 Week Low
- RAYA $0.56
- CVKD $5.70
- 52 Week High
- RAYA $1.90
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- RAYA 44.13
- CVKD 41.03
- Support Level
- RAYA $1.23
- CVKD $15.29
- Resistance Level
- RAYA $1.59
- CVKD $17.00
- Average True Range (ATR)
- RAYA 0.15
- CVKD 0.80
- MACD
- RAYA -0.04
- CVKD -0.02
- Stochastic Oscillator
- RAYA 14.75
- CVKD 9.50
About RAYA Erayak Power Solution Group Inc.
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from three products namely inverters, chargers, and gasoline generators. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.